E7080 is the most potent dual inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) as well as VEGF-R2 tyrosine kinase (IC50=4.0 nM) among those small-molecule inhibitors of VEGF-R kinases, such as sunitinib, sorafenib, and CEP-7055. It has been evaluated in vitro (pre-clinical) for anti-cancer effects. E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of angiogenesis and lymphangiogenesis.

June 21, 2017

prudect name : E7080 is the most potent dual inhibitor of VEGF-R3 tyrosine kinase (IC50=5.2 nM) as well as VEGF-R2 tyrosine kinase (IC50=4.0 nM) among those small-molecule inhibitors of VEGF-R kinases, such as sunitinib, sorafenib, and CEP-7055. It has been evaluated in vitro (pre-clinical) for anti-cancer effects. E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of angiogenesis and lymphangiogenesis.
E7080 lenvatinib

Synonyms: lenvatinibCAS NO: 417716-92-8Molecular Formula: C₂₁H₁₉ClN₄O₄Molecular Weight: 426.85Purity: 99%Solubility: In DMSOStorage: −20°C

PCI32765 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18512180